Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis

Journal of Chemical Information and Modeling

Volumn 49, Issue 2, 2009, Pages 308-317

  Scheiber, Josef ^a,b   Chen, Bin ^b   Milik, Mariusz ^b   Sukuru, Sai Chetan K ^b   Bender, Andreas ^b,c   Mikhailov, Dmitri ^b   Whitebread, Steven ^d   Hamon, Jacques ^a   Azzaoui, Kamal ^a   Urban, Laszlo ^d   Glick, Meir ^b   Davies, John W ^b   Jenkins, Jeremy L ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Novartis Institutes for Biomedical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS; TOXICITY;

CHEMICAL BIOLOGY; COMPREHENSIVE SYSTEM; DRUG CANDIDATES; GAINING INSIGHTS; LITERATURE DATA; NON-TOXIC COMPOUNDS; SYSTEMS BIOLOGY; TARGET PREDICTION;

CHEMICAL ANALYSIS;

ARTICLE; BAYES THEOREM; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; DRUG THERAPY; HUMAN; HYPOTENSION; RHABDOMYOLYSIS; SYSTEMS BIOLOGY;

BAYES THEOREM; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; HUMANS; HYPOTENSION; RHABDOMYOLYSIS; SYSTEMS BIOLOGY;

EID: 65249092595     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci800344p     Document Type: Article

References (71)

1. Giacomini, K. M.; Krauss, R. M.; Roden, D. M.; Eichelbaum, M.; Hayden, M. R.; Nakamura, Y. When good drugs go bad. Nature 2007, 446 (7139), 975-977.
2. Leone, R.; Sottosanti, L.; Luisa Iorio, M.; Santuccio, C.; Conforti, A.; Sabatini, V.; Moretti, U.; Venegoni, M. Drug-related deaths: an analysis of the italian spontaneous reporting database. Drug Saf. 2008, 31 (8), 703-713.
3. van der Hooft, C. S.; Sturkenboom, M. C. J. M.; van Grootheest, K.; Kingma, H. J.; Stricker, B. H. C. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006, 29 (2), 161-168.
4. Hughes, B. Vaccine partnerships to tackle neglected diseases. Nat. Rev. Drug Discovery 2008, 7 (4), 277-278.
5. Whitebread, S.; Hamon, J.; Bojanic, D.; Urban, L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discovery Today 2005, 10 (21), 1421-1433.
6. Hoffmann, P.; Warner, B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 2006, 53 (2), 87-8105.
7. Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58 (1), 32-45.
8. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J. Med. Chem. 2002, 45 (1), 137-142.
9. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440 (7083), 463-469.
10. Ekins, S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discovery Today 2008, 21, 1304-1314.
11. Ekins, S.; Erickson, J. A. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 2002, 30 (1), 96-99.
12. Bender, A.; Scheiber, J.; Glick, M.; Davies, J. W.; Azzaoui, K.; Hamon, J.; Urban, L.; Whitebread, S.; Jenkins, J. L. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2 (6), 861-873.
13. Ekins, S.; Andreyev, S.; Ryabov, A.; Kirillov, E.; Rakhmatulin, E. A.; Sorokina, S.; Bugrim, A.; Nikolskaya, T. A combined approach to drug metabolism and toxicity assessment. Drug Metab. Dispos. 2006, 34 (3), 495-503.
14. Jenkins, J. L.; Bender, A.; Davies, J. W. In silico target fishing: Predicting biological targets from chemical structure. Drug Discovery Today: Technol. 2006, 3 (4), 413-421.
15. Steindl, T. M.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. Highthroughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J. Comput.-Aided Mol. Des. 2006, 20 (12), 703-715.
16. Steindl, T. M.; Schuster, D.; Laggner, C.; Langer, T. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model. 2006, 46 (5), 2146-2157.
17. Steindl, T. M.; Schuster, D.; Laggner, C.; Chuang, K.; Hoffmann, R. D.; Langer, T. Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models. J. Chem. Inf. Model. 2007, 47 (2), 563-571.
18. Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol. 2007, 152 (1), 21-37.
19. Ekins, S.; Nikolsky, Y.; Nikolskaya, T. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 2005, 26 (4), 202-9.
20. Ekins, S. Systems-ADME/Tox: resources and network approaches. J. Pharmacol. Toxicol. Methods 2006, 53 (1), 38-66.
21. Oprea, T. I.; Tropsha, A.; Faulon, J. L.; Rintoul, M. D. Systems chemical biology. Nat. Chem. Biol. 2007, 3 (8), 447-450.
22. GVK-BIO. GVK Bio database suite. http://www.gvkbio.com (accessed January 15, 2008).
23. Sunset Molecular Discovery LLC. WOMBAT: World of Molecular Bioactivity. [2007.2]. http://www.sunsetmolecular.com (accessed January 15, 2008).
24. Symyx Technologies. MDL Drug Data Report. http://www.symyx. com (accessed January 15, 2008).
25. Ekins, S.; Bugrim, A.; Brovold, L.; Kirillov, E.; Nikolsky, Y.; Rakhmatulin, E.; Sorokina, S.; Ryabov, A.; Serebryiskaya, T.; Melnikov, A.; Metz, J.; Nikolskaya, T. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 2006, 36 (10-11), 877-901.
26. Elsevier. PharmaPendium. http://www.pharmapendium.com (accessed March 15, 2008).
27. MedDRA MSSO. MedDRA - the Medical Dictionary for Regulatory Activities; 2008.
28. GeneGo. MetaBase for Systems Biology and Bioinformatics. http:// www.genego.com (accessed January 15, 2008).
29. Pipeline Pilot. [6.1]; Scitegic, A. S. D. C: 2008.
30. Nidhi;Glick, M.; Davies, J. W.; Jenkins, J. L. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 2006, 46 (3), 1124-1133.
31. Xia, X.; Maliski, E. G.; Gallant, P.; Rogers, D. Classification of Kinase Inhibitors Using a Bayesian Model. J. Med. Chem. 2004, 47 (18), 4463-4470.
32. Klon, A. E.; Glick, M.; Davies, J. W. Combination of a Naive Bayes Classifier with Consensus Scoring Improves Enrichment of High-Throughput Docking Results. J. Med. Chem. 2004, 47 (18), 4356-4359.
33. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures Org. Biomol. Chem. 2004, 2 (22), 3256-3266.
34. Glen, R. C.; Bender, A.; Arnby, C. H.; Carlsson, L.; Boyer, S.; Smith, J. Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 2006, 9 (3), 199-204.
35. Bender, A.; Mussa, H. Y.; Glen, R. C.; Reiling, S. Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance. J. Chem. Inf. Comput. Sci. 2004, 44 (5), 1708-1718.
36. Klon, A. E.; Glick, M.; Davies, J. W. Application of Machine Learning To Improve the Results of High-Throughput Docking Against the HIV-1 Protease. J. Chem. Inf. Comput. Sci. 2004, 44 (6), 2216-2224.
37. Crisman, T. J.; Parker, C. N.; Jenkins, J. L.; Scheiber, J.; Thoma, M.; Kang, Z. B.; Kim, R.; Bender, A.; Nettles, J. H.; Davies, J. W.; Glick, M. Understanding False Positives in Reporter Gene Assays: in silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data. J. Chem. Inf. Model. 2007, 47 (4), 1319-1327.
38. Nettles, J. H.; Jenkins, J. L.; Bender, A.; Deng, Z.; Davies, J. W.; Glick, M. Bridging Chemical and Biological Space: 'Target Fishing" Using 2D and 3D Molecular Descriptors. J. Med. Chem. 2006, 49 (23), 6802-6810.
39. Yildirim, M. A.; Goh, K. I.; Cusick, M. E.; Barabasi, A. L.; Vidal, M. Drug-target network. Nat. Biotechnol. 2007, 25 (10), 1119-1126.
40. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36 (Database issue), 901-906.
41. Wishart, D. S. In silico drug exploration and discovery using DrugBank Current Protocols in Bioinformatics; 2007; Chapter 14.
42. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34 (Database issue), 668-672.
43. Evans, M.; Rees, A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same. Drug Saf. 2002, 25 (9), 649-663.
44. Furberg, C.; Pitt, B. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2001, 2 (5), 205-207.
45. Graham, D. J.; Staffa, J. A.; Shatin, D.; Andrade, S. E.; Schech, S. D.; La Grenade, L.; Gurwitz, J. H.; Chan, K. A.; Goodman, M. J.; Piatt, R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292 (21), 2585-2590.
46. Zeitlinger, M.; Muller, M. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]. Wien. Med. Wochenschr. 2003, 153 (11-12), 250-254.
47. Saito, M.; Hirata-Koizumi, M.; Miyake, S.; Hasegawa, R. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Kokuritsu lyakuhin Shokuhin Eisei Kenkyusho Hokoku 2005, (123), 41-45.
48. Chen, X. H.; Geller, E. B.; DeRiel, J. K.; Liu-Chen, L. Y.; Adler, M. W. Antisense confirmation of mu- and kappa-opioid receptor mediation of morphine's effects on body temperature in rats. Drug Alcohol Depend. 1996, 43 (3), 119-124.
49. Wang, Y. X.; Xu, W. G.; Sun, X. J.; Chen, Y. Z.; Liu, X. Y.; Tang, H.; Jiang, C. L. Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2. J. Neuroimmunol. 2004, 156 (1- 2), 107-112.
50. Vezzosi, D.; Bennet, A.; Courbon, F.; Caron, P. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin. Endocrinol. (Oxford, U.K.) 2008, 68 (6), 904-911.
51. Huerta-Alardin, A. L.; Varon, J.; Marik, P. E. Bench-to-bedside review: Rhabdomyolysis - an overview for clinicians. Crit. Care 2005, 9 (2), 158-169.
52. Armitage, J. The safety of statins in clinical practice. Lancet 2007, 370 (9601), 1781-1790.
53. Harper, C. R.; Jacobson, T. A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 2007, 18 (4), 401-408.
54. Zarowitz, B. J. Fixed-dose combinations for improving medication adherence in assisted living environments. Geriatr. Nurs. 2007, 28 (6), 341-345.
55. Radcliffe, K. A.; Campbell, W. W. Statin myopathy. Curr. Neurol. Neurosci. Rep. 2008, 8 (1), 66-72.
56. Ueda, S. Drug-induced rhabdomyolysis]. Nippon Rinsho 2007, 65 Suppl 8, 567-571.
57. Sprague, J. E.; Brutcher, R. E.; Mills, E. M.; Caden, D.; Rusyniak, D. E. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with alphal- plus beta3-adrenoreceptor antagonists. Br. J. Pharmacol. 2004, 142 (4), 667-670.
58. Chong, C. R.; Sullivan, D. J. New uses for old drugs. Nature 2007, 448 (7154), 645-646.
59. Lehrer, S.; Rabin, J.; Kalir, T.; Schachter, B. S. Estrogen receptor variant and hypertension in women. Hypertension 1993, 21 (4), 439-441.
60. Tabara, Y.; Tachibana-Iimori, R.; Yamamoto, M.; Abe, M.; Kondo, I.; Miki, T.; Kohara, K. Hypotension associated with prone body position: a possible overlooked postural hypotension. Hypertens. Res. 2005, 28 (9), 741-746.
61. Head, G. A.; Obeyesekere, V. R.; Jones, M. E.; Simpson, E. R.; Krozowski, Z. S. Aromatase-deficient (ArKO) mice have reduced blood pressure and baroreflex sensitivity. Endocrinology 2004, 145 (9), 4286-4291.
62. Murakami, M.; Yamamura, H.; Suzuki, T.; Kang, M. G.; Ohya, S.; Murakami, A.; Miyoshi, I.; Sasano, H.; Muraki, K.; Hano, T.; Kasai, N.; Nakayama, S.; Campbell, K. P.; Flockerzi, V.; Imaizumi, Y.; Yanagisawa, T.; Iijima, T. Modified cardiovascular L-type channels in mice lacking the voltage-dependent Ca2+ channel beta3 subunit. J. Biol. Chem. 2003, 278 (44), 43261-43267.
63. Zhao, Q.; Wang, X.; Nelin, L. D.; Yao, Y.; Matta, R.; Manson, M. E.; Baliga, R. S.; Meng, X.; Smith, C. V.; Bauer, J. A.; Chang, C. H.; Liu, Y. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 2006, 203 (1), 131-140.
64. Chaudhari, N. A single nucleotide deletion in the skeletal muscle-specific calcium channel transcript of muscular dysgenesis (mdg) mice. J. Biol. Chem. 1992, 267 (36), 25636-25639.
65. Yang, Z. Z.; Tschopp, O.; Di-Poi, N.; Bruder, E.; Baudry, A.; Dummler, B.; Wahli, W.; Hemmings, B. A. Dosage-dependent effects of Aktl/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell. Biol. 2005, 25 (23), 10407-10418.
66. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs. Curr. Opin. Struct. Biol. 2006, 16 (1), 127-136.
67. PubChem. http://pubchem.ncbi.nlm.nih.gov/ (accessed January 15, 2008).
68. NIMH Psychoactive Drug Screening Program. The NIMH PDSP is Directed by Bryan L. Roth, 2008.
69. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discovery 2004, 3 (4), 353-359.
70. Strachan, R. T.; Ferrara, G.; Roth, B. L. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discovery Today 2006, 11 (15-16), 708-716.
71. Editorial. All systems go. Nat. Rev. Drug Discovery 2008, 7 (4), 278-279.